Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 497

1.

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ.

Diabetes Obes Metab. 2013 Aug;15(8):721-8. doi: 10.1111/dom.12081.

PMID:
23398530
2.

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ.

Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185.

PMID:
23906374
3.

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.

Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ.

Diabetes Obes Metab. 2013 Jul;15(7):613-21. doi: 10.1111/dom.12073.

PMID:
23356556
4.

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.

Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG PIO™ trial investigators..

Diabetes Obes Metab. 2014 Feb;16(2):147-58. doi: 10.1111/dom.12188.

PMID:
23906415
5.

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.

Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ PIO investigators..

Clin Ther. 2015 Aug;37(8):1773-88.e1. doi: 10.1016/j.clinthera.2015.05.511.

PMID:
26138864
6.

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF.

Diabet Med. 2015 Apr;32(4):531-41. doi: 10.1111/dme.12624.

PMID:
25381876
7.

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC; EMPA-REG MDI Trial Investigators..

Diabetes Care. 2014 Jul;37(7):1815-23. doi: 10.2337/dc13-3055.

PMID:
24929430
8.

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.

Schumm-Draeger PM, Burgess L, Korányi L, Hruba V, Hamer-Maansson JE, de Bruin TW.

Diabetes Obes Metab. 2015 Jan;17(1):42-51. doi: 10.1111/dom.12387.

PMID:
25200570
9.

Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.

Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, Woerle HJ, Broedl UC.

Adv Ther. 2014 Jun;31(6):621-38. doi: 10.1007/s12325-014-0126-8.

PMID:
24958326
10.

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.

Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ METSU investigators..

Diabetes Res Clin Pract. 2015 Oct;110(1):82-90. doi: 10.1016/j.diabres.2015.05.044.

PMID:
26324220
11.

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A.

Diabetes Obes Metab. 2013 May;15(5):403-9. doi: 10.1111/dom.12038.

PMID:
23163880
12.

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators..

Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Erratum in: Lancet Diabetes Endocrinol. 2015 Sept;3(9):e7.

PMID:
24948511
13.

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM trial investigators..

Diabetes Obes Metab. 2015 Oct;17(10):936-48. doi: 10.1111/dom.12503.

14.

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group..

Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187.

PMID:
23911013
15.

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ; EMPA-REG MET Trial Investigators..

Diabetes Care. 2014 Jun;37(6):1650-9. doi: 10.2337/dc13-2105.

PMID:
24722494
16.

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group..

Diabetes Care. 2014;37(3):740-50. doi: 10.2337/dc13-0467.

PMID:
24144654
17.

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.

Ji L, Han P, Liu Y, Yang G, Dieu Van NK, Vijapurkar U, Qiu R, Meininger G.

Diabetes Obes Metab. 2015 Jan;17(1):23-31. doi: 10.1111/dom.12385.

PMID:
25175734
18.

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.

DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC.

Diabetes Care. 2015 Mar;38(3):384-93. doi: 10.2337/dc14-2364. Erratum in: Diabetes Care. 2015 Jun;38(6):1173.

PMID:
25583754
19.

Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.

Zhao X, Cui Y, Zhao S, Lang B, Broedl UC, Salsali A, Pinnetti S, Macha S.

Clin Ther. 2015 Jul 1;37(7):1493-502. doi: 10.1016/j.clinthera.2015.05.001.

PMID:
26101175
20.

Empagliflozin as add-on to metformin in people with Type 2 diabetes.

Merker L, Häring HU, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND MET investigators..

Diabet Med. 2015 Dec;32(12):1555-67. doi: 10.1111/dme.12814.

PMID:
26031566
Items per page

Supplemental Content

Support Center